✦ LIBER ✦

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

✍ Scribed by Ahmadi, Tahamtan; Chong, Elise A.; Gordon, Amanda; Aqui, Nicole A.; Nasta, Sunita D.; Svoboda, Jakub; Mato, Anthony R.; Schuster, Stephen J.

Book ID: 125469509
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 250 KB
Volume: 120
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.28405

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab combined with cladribine or wi

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

✍ Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Anna Szmigielska-Kaplon; Krzyszt 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Proliferation predicts failure-free surv

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine

✍ Mar Garcia; Jorge E. Romaguera; Kedar V. Inamdar; George Z. Rassidakis; L. Jeffr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB 👁 1 views

24 In vivo purging and post transplant i

24 In vivo purging and post transplant immunotherapy with rituximab produces durable remissions in patients with low grade and mantle cell lymphoma

✍ I.W. Flinn; L. Diehl; E. Garrett; D. Carter-Brookins; A. Goodrich; K. Loper; R.J 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 278 KB

Durable responses with the metronomic ri

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

✍ Jia Ruan; Peter Martin; Morton Coleman; Richard R. Furman; Ken Cheung; Adam Faye 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 503 KB

Durable complete responses from therapy

Durable complete responses from therapy with combined epratuzumab and rituximab : Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma

✍ John P. Leonard; Stephen J. Schuster; Christos Emmanouilides; Felix Couture; Nic 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract ## BACKGROUND. In this international, multicenter trial, the authors evaluated rituximab (anti‐CD20) plus epratuzumab (anti‐CD22) in patients with postchemotherapy relapsed/refractory, indolent non‐Hodgkin lymphoma (NHL), including long‐term efficacy. ## METHODS. Forty‐nine patients

Pixantrone dimaleate in combination with

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort

✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone